Following extensive research, we have built a set of Personalised Support Services for cancer patients. These services are based on research and guidelines and offer evidence-based approaches to improve quality of life, while strengthening the relationship between the patient and their medical team.

They have been built by analysing thousands of scientific publications from high impact factor journals, as well as guidelines, medical literature, and databases. This allows CareAcross to match every patient’s needs with the most appropriate support.

We offer services among the following: 

• Breast cancer
• Lung cancer
• Bowel cancer
• Prostate cancer
• Other cancer types

CareAcross is a digital health company focusing on cancer. It provides 100% personalised support to people affected by cancer through reliable information, useful tools, psychological support & guidance from experts. Its vision is to facilitate faster, more effective oncology research, and interactions that will improve quality of life of patients and caregivers.

DiagMMR is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing Lynch syndrome related cancers.

While current Lynch syndrome diagnosis relies heavily on tumor studies, the quantitative DiagMMR method allows carrier diagnosis based on a minimally invasive tissue sample before the person has developed any cancer, without the knowledge and details of an inherited mutation.

The inherent challenges to variant interpretation in genetic testing can be avoided and the conclusive and actionable results removes the burden of uncertainty from both the patients and the treating medical professionals.

LS CancerDiag Ltd is committed to reducing cancer mortality rates with a low-cost, simple diagnostic method that detects an inherited cancer-causing condition prior to cancer. Their vision is to see DiagMMR™ as a new global testing standard in LS diagnostics. Lynch syndrome is the main cause of hereditary colorectal cancers and it also causes a broad spectrum of other tumors. With a significant proportion of the world’s population carrying the Lynch syndrome mutation, there are potentially tens of millions under a severe risk for being affected by LS. Their groundbreaking DiagMMR™ assay is an easy functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary Non­Polyposis Colorectal Cancer; HNPCC). Their mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome by delivering predictive and accurate results with a fast, unique and cost-efficient method globally.